Literature DB >> 25670643

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.

F Danion1, E Belissa2, G Peytavin3, E Thierry4, F Lanternier1, A Scemla5, O Lortholary1, O Delelis4, V Avettand-Fenoel6, C Duvivier7.   

Abstract

Entities:  

Keywords:  E157Q mutation; HIV treatment; INSTIs; dolutegravir resistance; integrase strand transfer inhibitors

Mesh：

Substances：

Year:  2015        PMID： 25670643     DOI： 10.1093/jac/dkv012

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.

Authors:  Kaitlin Anstett; Vincent Cutillas; Robert Fusco; Thibault Mesplède; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

2.  Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Authors:  Emmanuel Ndashimye; Mariano Avino; Fred Kyeyune; Immaculate Nankya; Richard M Gibson; Eva Nabulime; Art F Y Poon; Cissy Kityo; Peter Mugyenyi; Miguel E Quiñones-Mateu; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2018-02-26       Impact factor: 2.205

3.  Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States.

Authors:  Iris Chen; Yinfeng Zhang; Vanessa Cummings; Gavin A Cloherty; Matthew Connor; Geetha Beauchamp; Sam Griffith; Scott Rose; Joel Gallant; Hyman M Scott; Steven Shoptaw; Carlos Del Rio; Irene Kuo; Sharon Mannheimer; Hong-Van Tieu; Christopher B Hurt; Sheldon D Fields; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-06       Impact factor: 2.205

4.  Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.

Authors:  Kaitlin Anstett; Robert Fusco; Vincent Cutillas; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

Review 5.  HIV drug resistance against strand transfer integrase inhibitors.

Authors:  Kaitlin Anstett; Bluma Brenner; Thibault Mesplede; Mark A Wainberg
Journal:  Retrovirology       Date:  2017-06-05       Impact factor: 4.602

6.  Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Authors:  Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Kaitlin Anstett; Thibault Mésplède; Jean-Pierre Routy; Marjorie A Robbins; Bluma G Brenner
Journal:  Retrovirology       Date:  2018-08-17       Impact factor: 4.602

Review 7.  Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.

Authors:  Charlotte Charpentier; Diane Descamps
Journal:  Viruses       Date:  2018-01-18       Impact factor: 5.048

8.  Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.

Authors:  Roger Paredes; Philip L Tzou; Gert van Zyl; Geoff Barrow; Ricardo Camacho; Sergio Carmona; Philip M Grant; Ravindra K Gupta; Raph L Hamers; P Richard Harrigan; Michael R Jordan; Rami Kantor; David A Katzenstein; Daniel R Kuritzkes; Frank Maldarelli; Dan Otelea; Carole L Wallis; Jonathan M Schapiro; Robert W Shafer
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.752
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.